Researchers assessed the effect of treatment with glucocorticoids and tocilizumab in patients with severe COVID-19-associated cytokine storm syndrome.
The incidence of hip fracture decreased from 1970 to 2010 in the US.
The impact of glucocorticoid treatment on patients with COVID-19 varies according to C-reactive protein levels.
The American College of Rheumatology updated its COVID-19 guidance for the management of adult patients with rheumatic diseases.
Early treatment with glucocorticoids may be beneficial for patients hospitalized with COVID-19 who have high levels of inflammation due to the disease.
Low hemoglobin A1c and low body mass index are associated with higher risk for bone fracture in individuals with type 2 diabetes.
The nonreplicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine appears safe and induces immune responses.
Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.
Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses.
Researchers investigated the clinical characteristics and outcomes of COVID-19 infection in patients with vs without rheumatic disease.
This is the first study to describe the safety of IL-6 blockade with intravenous sarilumab in patients with COVID-19 pneumonia with systemic hyperinflammation.
For patients with COVID-19 requiring mechanical ventilation, tocilizumab is associated with improved survival.
The Norfolk Arthritis Register has released an interim report on the impact of COVID-19 restrictions on people living with inflammatory arthritis.
Experts highlight the need for cancer screening strategies in patients with rheumatic diseases.
The American College of Rheumatology has issued a set of position statements for the use of telemedicine in the management of patients with rheumatic diseases.